Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study

Table 2 Variance in preoperative clinicopathological parameters between patients with and without seminal vesicle involvement (SVI)

	SVI present (n = 8)	SVI absent (n = 116)	Univariate	Multivariate
	SVI present (n = 8)	SVI absent (n = 116)	P value	P value	Adjusted odds ratio (95% CI)
Mean age [years]	63.6 ± 3.9	63.9 ± 5.1	0.725
PSA [ng/ml]	13.0 ± 8.1	8.7 ± 7.2	0.105
Gleason score at biopsy	8.1 ± 1.1	7.0 ± 1.0	0.005
cT stage (n)			0.153
T1c	5 (62.5%)	94 (81.0%)
T2	3 (37.5%)	15 (12.9%)
T3a	0 (0%)	7 (6.0%)
%positive cores	31.0 ± 21.3	21.3 ±16.4	0.242
TZ biopsy positive (n)	7 (87.5%)	35 (30.2%)	0.002	0.023	12.99 (1.490-111.1)
Number of apex-positive (2–4/0–1) (n)	3/5	26/90	0.278
Number of middle-positive (2–4/0–1) (n)	6/2	28/88	0.005	0.025	7.299 (1.312-40.00)
Number of base-positive (2–4/0–1) (n)	4/4	23/93	0.067

PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy.

ISSN: 1746-1596